Drug Details
| General Information of the Drug (ID: DR7572) | ||||
|---|---|---|---|---|
| Name |
PHA665752
|
|||
| Synonyms |
PHA-665752; 477575-56-7; PHA 665752; TCMDC-125885; UNII-0VXU5T5R3J; (2R)-1-[[5-[(Z)-[5-[[(2,6-DICHLOROPHENYL)METHYL]SULFONYL]-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE]METHYL]-2,4-DIMETHYL-1H-PYRROL-3-YL]CARBONYL]-2-(1-PYRROLIDINYLMETHYL)PYRROLIDINE; 0VXU5T5R3J; CHEMBL450786; CHEBI:90197; (R,Z)-5-(2,6-dichlorobenzylsulfonyl)-3-((3,5-dimethyl-4-(2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl)methylene)indolin-2-one; PHA-665752 hydrate
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Investigative | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C32H34Cl2N4O4S
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC1=C(NC(=C1C(=O)N2CCCC2CN3CCCC3)C)C=C4C5=C(C=CC(=C5)S(=O)(=O)CC6=C(C=CC=C6Cl)Cl)NC4=O
|
|||
| InChI |
1S/C32H34Cl2N4O4S/c1-19-29(35-20(2)30(19)32(40)38-14-6-7-21(38)17-37-12-3-4-13-37)16-24-23-15-22(10-11-28(23)36-31(24)39)43(41,42)18-25-26(33)8-5-9-27(25)34/h5,8-11,15-16,21,35H,3-4,6-7,12-14,17-18H2,1-2H3,(H,36,39)/b24-16-/t21-/m1/s1
|
|||
| InChIKey |
OYONTEXKYJZFHA-SSHUPFPWSA-N
|
|||
| CAS Number |
CAS 477575-56-7
|
|||
| GDSC | ||||
| TTD Drug ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Celastrol | Celastrus strigillosus | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP7 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | BEL-7402 | CVCL_5492 | Human hepatocellular carcinoma | Homo sapiens | ||
| Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | |||
| In-vivo Model | Male nude mice (4-6 weeks) were inoculated subcutaneously with human liver cancer cell lines Huh7. | |||||
| Experimental
Result(s) |
Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Proto-oncogene c-Met (MET) | Molecule Info | [3] | |
| KEGG Pathway | Ras signaling pathway | Click to Show/Hide | ||
| 2 | Rap1 signaling pathway | |||
| 3 | Cytokine-cytokine receptor interaction | |||
| 4 | Endocytosis | |||
| 5 | PI3K-Akt signaling pathway | |||
| 6 | Axon guidance | |||
| 7 | Focal adhesion | |||
| 8 | Adherens junction | |||
| 9 | Bacterial invasion of epithelial cells | |||
| 10 | Epithelial cell signaling in Helicobacter pylori infection | |||
| 11 | Malaria | |||
| 12 | Pathways in cancer | |||
| 13 | Transcriptional misregulation in cancer | |||
| 14 | Proteoglycans in cancer | |||
| 15 | MicroRNAs in cancer | |||
| 16 | Renal cell carcinoma | |||
| 17 | Melanoma | |||
| 18 | Central carbon metabolism in cancer | |||
| Pathway Interaction Database | Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | Click to Show/Hide | ||
| 2 | Arf6 signaling events | |||
| 3 | Signaling events mediated by TCPTP | |||
| 4 | Posttranslational regulation of adherens junction stability and dissassembly | |||
| 5 | Direct p53 effectors | |||
| 6 | Syndecan-1-mediated signaling events | |||
| 7 | Stabilization and expansion of the E-cadherin adherens junction | |||
| 8 | a6b1 and a6b4 Integrin signaling | |||
| 9 | FGF signaling pathway | |||
| 10 | Regulation of retinoblastoma protein | |||
| Reactome | Sema4D mediated inhibition of cell attachment and migration | Click to Show/Hide | ||
| WikiPathways | TGF beta Signaling Pathway | Click to Show/Hide | ||
| 2 | Signaling of Hepatocyte Growth Factor Receptor | |||
| 3 | Focal Adhesion | |||
| 4 | Extracellular vesicle-mediated signaling in recipient cells | |||
| 5 | Signaling Pathways in Glioblastoma | |||
| 6 | miR-targeted genes in squamous cell - TarBase | |||
| 7 | miR-targeted genes in muscle cell - TarBase | |||
| 8 | miR-targeted genes in lymphocytes - TarBase | |||
| 9 | miR-targeted genes in epithelium - TarBase | |||
| 10 | Semaphorin interactions | |||
